Functional polyesters enable selective siRNA delivery to lung cancer over matched normal cells
Yunfeng Yan1, Li Liu2, Hu Xiong1
1Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX 75390; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX 75390;
Summary
Researchers developed functional polyester nanoparticles that selectively deliver siRNA drugs to lung cancer cells, not normal cells. This targeted approach enhances cancer cell apoptosis and suppresses tumor growth, reducing side effects.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Cancer Therapeutics
Background:
- Conventional chemotherapy lacks selectivity, causing significant side effects due to non-specific targeting of rapidly dividing cells.
- Developing targeted drug delivery systems is crucial for improving cancer treatment efficacy and reducing toxicity.
Purpose of the Study:
- To discover and characterize functional polyesters for selective siRNA drug delivery to lung cancer cells.
- To evaluate the efficacy and safety of these selective nanoparticles in preclinical cancer models.
Main Methods:
- High-throughput screening of polyester libraries against matched cancer and normal lung cell lines.
- In vitro assessment of nanoparticle endocytosis and cellular uptake.
- In vivo evaluation of nanoparticle biodistribution, tumor retention, and therapeutic efficacy in mouse xenograft models.
Main Results:
- Selective polyplex nanoparticles (NPs) demonstrated rapid endocytosis in lung cancer cells (HCC4017) but were arrested in normal lung cells (HBEC30-KT).
- Cancer-selective NPs showed prolonged retention in tumor xenografts (>1 week) compared to nonselective NPs (cleared within hours).
- Selective NPs significantly enhanced siRNA-mediated cancer cell apoptosis and suppressed tumor growth, with successful gene silencing achieved via i.v. injection and aerosol inhalation.
Conclusions:
- Functional polyester nanoparticles can be designed for selective delivery to cancer cells without targeting ligands.
- This selective nanoparticle approach offers a promising strategy to improve cancer therapy efficacy and minimize adverse side effects.
- Cellular response heterogeneity to drug carriers is a critical consideration for nanoparticle-based drug delivery system design.
